IPHA: רווח נקי למניה (EPS TTM) Innate Pharma, S.A.

The development of unique molecules to activate immunity against tumors supports an upward trend for Innate Pharma S.A. (IPHA), where the net income per share over the last 12 months recorded a fresh value of -0.59. Stable management relies on large-scale R&D alliances with pharma behemoths, while optimized international antibody logistics minimize customs risks, ensuring high profitability across the entire supply chain.

For the French developer of immuno-oncology drugs, whose operations are protected by international humanitarian status, the rolling 12-month EPS serves as an indicator of the efficiency of R&D cycle monetization. This metric is calculated as the ratio of total net income to the number of shares outstanding, allowing investors to assess the real return on each share and the sustainability of the Innate Pharma S.A. (IPHA) business model amid global clinical trials.